Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24367151 | 0.83 | GAA (0.42) | GAA | |
| SCHEMBL30470979 | 0.83 | GAA (0.42) | GAA | |
| SCHEMBL25197257 | 0.83 | DGAT1 (0.37) | TYK2SCN9AGAANNMTIRAK4 | |
| SCHEMBL24363781 | 0.78 | NNMT (0.47) | GAANNMTMKNK1MKNK2ROCK2 | |
| SCHEMBL24363752 | 0.77 | TYK2 (0.42) | TYK2SCN9ANNMTIRAK4SYK | |
| SCHEMBL27042313 | 0.73 | HCRTR1 (0.34) | GAA | |
| SCHEMBL17292928 | 0.73 | HCRTR1 (0.34) | SCN9APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20524513 | 0.72 | RAB9A (0.54) | TYK2IRAK4LMNAROCK2 | |
| SCHEMBL24367112 | 0.71 | PIK3CB (0.50) | GAANNMTIRAK4MKNK2LMNA | |
| SCHEMBL29499567 | 0.70 | MKNK1 (0.42) | TYK2NNMTIRAK4MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TYK2 2864/4885SCN9A 1018/4885GAA 889/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TYK2 4588/4885SCN9A 411/4885GAA 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.